Abstract:Epidemiological and experimental studies suggest that a disease-aggravating neuroinflammatory process is present at preclinical stages of Alzheimer's disease. Given that individuals with Down syndrome are at increased genetic risk of Alzheimer's disease and therefore develop the spectrum of Alzheimer's neuropathology in a uniform manner, they constitute an important population to study the evolution of neuroinflammation across the Alzheimer's continuum. Therefore, in this cross-sectional study, we characterized the brain inflammatory profile across the lifespan of individuals with Down syndrome. Microglial morphology and inflammatory cytokine expression were analysed by immunohistochemistry and electrochemiluminescent-based immunoassays in the frontal cortex from foetuses to adults with Down syndrome and control subjects (16 gestational weeks to 64 years), totalling 127 cases. Cytokine expression in mixed foetal primary cultures and hippocampus of adults with Down syndrome, as well as the effects of sex on cytokine expression were also analysed. A higher microglial soma size-to-process length ratio was observed in the frontal cortex of children and young adults with Down syndrome before the development of full-blown Alzheimer's pathology. Moreover, young adults with Down syndrome also displayed increased numbers of rod-like microglia. Increased levels of interleukin-8 and interleukin-10 were observed in children with Down syndrome (1-10 years; Down syndrome n = 5, controls n = 10) and higher levels of interleukin-1β, interleukin-1α, interleukin-6, interleukin-8, interleukin-10, interleukin-15, eotaxin-3, interferon gamma-induced protein 10, macrophage-derived chemokine, and macrophage inflammatory protein-beta, were found in young adults with Down syndrome compared to euploid cases (13-25 years, Down syndrome n = 6, controls n = 24). Increased cytokine expression was also found in the conditioned media of mixed cortical primary cultures from second trimester foetuses with Down syndrome (Down syndrome n = 7, controls n = 7). Older adults with Down syndrome (39-68 years, Down syndrome n = 22, controls n = 16) displayed reduced levels of interleukin-10, interleukin-12p40, interferon-gamma and tumour necrosis factor-alpha. Microglia displayed larger somas and shorter processes. Moreover, an increase in dystrophic microglia and rod-like microglia aligning to neurons harbouring tau pathology were also observed. Sex stratification analyses revealed that females with Down syndrome had increased interleukin-6 and interleukin-8 levels compared to males with Down syndrome. Finally, multivariate projection methods identified specific cytokine patterns among individuals with Down syndrome. Our findings indicate the presence of an early and evolving neuroinflammatory phenotype across the lifespan in Down syndrome, a knowledge that is relevant for the discovery of stage-specific targets and for the design of possible anti-inflammatory trials against Alzheimer's disease in this population.

Dysregulation of the Immune System in a Natural History Study of 1299 Individuals with Down Syndrome

Immune Dysregulation in Children With Down Syndrome

Down Syndrome and Autoimmune Disease

Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells

Down Syndrome in Children: A Primary Immunodeficiency with Immune Dysregulation

The immunoreactive signature of monocyte-derived dendritic cells from patients with Down syndrome

Partial impairment of immune functions in peripheral blood leukocytes from aged men with Down's syndrome

Comprehensive Assessment of Dermatologic and Dysmorphic Manifestations in Patients With Down Syndrome

Dermatologic Conditions in Down Syndrome: A Multi‐Site Retrospective Review of International Classification of Diseases Codes

Genome-wide expression analysis in Down syndrome: insight into immunodeficiency

Aberrations in Circulating Inflammatory Cytokine Levels in Patients with Down Syndrome: a Meta-Analysis

COVID‐19 in patients with Down syndrome: A systematic review

De novo variants in immune regulatory genes in Down syndrome regression disorder

Susceptibility to COVID-19 Diagnosis in People with Down Syndrome Compared to the General Population: Matched-Cohort Study Using Primary Care Electronic Records in the UK

Evolution of neuroinflammation across the lifespan of individuals with Down syndrome

Altered peripheral blood leukocyte subpopulations, function, and gene expression in children with Down Syndrome: Implications for respiratory tract infection

What people with Down Syndrome can teach us about cardiopulmonary disease

Enhancing understanding of SARS-CoV-2 infection among individuals with Down syndrome: An integrative review

Prevalence and diversity of retinal disease in adults with Down syndrome

Immune and TRG repertoire signature of the thymus in Down syndrome patients

Immunotherapy in selected patients with Down syndrome disintegrative disorder